To quantitatively describe the nature, severity, and duration of symptoms and functional impairment during recovery from transurethral resection of bladder tumors.
All patients scheduled for transurethral resection were approached for enrollment in a text-message based ecological momentary symptom assessment platform.
Nine patients reported outcomes were measured 7 days before surgery and on postoperative days 1, 2, 3, 5, 7, 10, and 14 using a 5-point Likert scale. Self-reported degree of hematuria was collected using a visual scale. Clinical data was collected via retrospective chart review.
A total of 159 patients were analyzed. Postoperative symptoms were overall mild, with the largest differences from baseline to postoperative day 1 seen in dysuria (median 0/5 vs. 3/5) and ability to work (median 5/5 vs. 4/5). Recovery was generally rapid, with 76% of patients reporting ≥4/5 agreement with the statement "I feel recovered from surgery" by postoperative day 2, although 15% of patients reported persistently lower levels of agreement on postoperative day 10 or 14. Patients undergoing larger resections (≥2cm) did take longer to return to baseline in multiple symptom domains, but the difference of medians vs. those undergoing smaller resections was less than 1 day across all domains. Multivariable analysis suggested that receiving perioperative intravesical chemotherapy was associated with longer time to recovery. 84% of patients reported clear yellow urine by postoperative day 3.
In this population, hematuria and negative effects on quality of life resulting from transurethral resection of bladder tumors were generally mild and short-lived, although a small number of patients experienced longer recoveries.
Urologic oncology. 2024 Feb 17 [Epub ahead of print]
Marshall Strother, Ryan Barlotta, Robert Uzzo, Evan Bloom, Seyed B Jazayeri, Alberto C Bigalli, Jared Schober, Jennifer Lee, Adrien Bernstein, Kevin Ginsburg, Elizabeth Handorf, David Yt Chen, Andres Correa, Richard Greenberg, Marc Smaldone, Rosalia Viterbo, Alexander Kutikov
Department of Urology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: ., Department of Urology, Fox Chase Cancer Center, Philadelphia, PA., Department of Urology, University of Florida Jacksonville, Jacksonville, FL., Lewis Katz School of Medicine at Temple University, Philadelphia, PA., Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38369443